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Abstract: Cellular and viral factors participate in the replication cycle of rotavirus. We report that
the guanine nucleotide exchange factor GBF1, which activates the small GTPase Arf1 to induce COPI
transport processes, is required for rotavirus replication since knocking down GBF1 expression by RNA
interference, or inhibiting its activity by treatment with Brefeldin A (BFA) or Golgicide A (GCA) sig-
nificantly reduce the yield of infectious viral progeny. This reduction in virus yield was related to a
block in virus assembly since in the presence of either BFA or GCA the assembly of infectious mature
triple-layered virions was significantly prevented and only doubled layered-particles were detected. We
report that the catalytic activity of GBF1, but not the activation of Arf1, is essential for the assembly of
the outer capsid of rotavirus. We show that both BFA and GCA, as well as interfering with the synthesis
of GBF1, alter the electrophoretic mobility of glycoproteins VP7 and NSP4 and block the trimerization
of the virus surface VP7, a step required for its incorporation into virus particles. Although a post-
translational modification of VP7 (other than glycosylation) could be related to the lack of trimerization,
we found that NSP4 might also be involved in this process, since knocking-down its expression reduces
VP7 trimerizarion. In support, recombinant VP7 protein overexpressed in transfected cells formed trimers
only when co-transfected with NSP4. <jats:bold>IMPORTANCE</jats:bold> Rotavirus, a member of
the family Reoviridae, is the major cause of severe diarrhea in children and young animals worldwide.
Despite the significant advances in the characterization of the biology of this virus, the mechanisms in-
volved in morphogenesis of the virus particle are still poorly understood. In this work, we show that
the guanine nucleotide exchange factor GBF1, relevant for the COPI/Arf1-mediated cellular vesicular
transport, participates in the replication cycle of the virus, influencing the correct processing of viral
glycoproteins VP7 and NSP4, and the assembly of the virus surface proteins VP7 and VP4.
DOI: https://doi.org/10.1128/jvi.01062-19
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Cellular and viral factors participate in the replication cycle of rotavirus. We report that the 20 
guanine nucleotide exchange factor GBF1, which activates the small GTPase Arf1 to 21 
induce COPI transport processes, is required for rotavirus replication since knocking down 22 
GBF1 expression by RNA interference, or inhibiting its activity by treatment with 23 
Brefeldin A (BFA) or Golgicide A (GCA) significantly reduce the yield of infectious viral 24 
progeny. This reduction in virus yield was related to a block in virus assembly since in the 25 
presence of either BFA or GCA the assembly of infectious mature triple-layered virions 26 
was significantly prevented and only doubled layered-particles were detected. We report 27 
that the catalytic activity of GBF1, but not the activation of Arf1, is essential for the 28 
assembly of the outer capsid of rotavirus. We show that both BFA and GCA, as well as 29 
interfering with the synthesis of GBF1, alter the electrophoretic mobility of glycoproteins 30 
VP7 and NSP4 and block the trimerization of the virus surface VP7, a step required for its 31 
incorporation into virus particles. Although a post-translational modification of VP7 (other 32 
than glycosylation) could be related to the lack of trimerization, we found that NSP4 might 33 
also be involved in this process, since knocking-down its expression reduces VP7 34 
trimerizarion. In support, recombinant VP7 protein overexpressed in transfected cells 35 















































Rotavirus, a member of the family Reoviridae, is the major cause of severe diarrhea in 41 
children and young animals worldwide. Despite the significant  advances in the 42 
characterization of the  biology of this virus, the mechanisms involved in morphogenesis of 43 
the virus particle are still poorly understood. In this work, we show that the guanine 44 
nucleotide exchange factor GBF1, relevant for the COPI/Arf1-mediated cellular vesicular 45 
transport, participates in the replication cycle of the virus, influencing the correct 46 
processing of viral glycoproteins VP7 and NSP4, and the assembly of the virus surface 47 






















































Rotaviruses, members of the family Reoviridae, are non-enveloped particles formed by 60 
three concentric layers of proteins that surround the eleven genome segments of double-61 
stranded RNA (dsRNA). The innermost layer is composed of the core-shell proteinVP2 that 62 
encloses the replication intermediates, composed of the RNA dependent RNA polymerase 63 
VP1, and the guanylyl-methyl transferase, VP3. The intermediate layer is formed by VP6 64 
that surrounds the VP2 layer to form double-layered particles (DLPs). Finally, the addition 65 
of the glycoprotein VP7 and the spike protein VP4 onto the DLPs forms the infectious 66 
triple-layered particles (TLPs) (1, 2). 67 
The replication of rotavirus occurs in cytoplasmic non-membranous electron-dense 68 
inclusions termed viroplasms composed of NSP2, NSP5, VP1, VP2, VP6 and host 69 
components (1, 3). The replication and packaging of the viral genome into newly 70 
synthesized DLPs take place in these inclusions (4), which then bud into the lumen of the 71 
endoplasmic reticulum (ER) through membrane sites modified by the presence of NSP4 (5, 72 
6). NSP4 is a transmembrane ER glycoprotein with two N-linked high mannose 73 
glycosylated chains (7) that play a crucial role in the last steps of rotavirus assembly. It has 74 
been shown that the cytoplasm oriented-terminus of NSP4 associates with VP4 (8), and 75 
binds the VP6 on DLPs acting as a receptor for these particles to mediate their budding into 76 
the ER (9, 10). Moreover, NSP4 has been shown to also interact with VP7 through its N-77 
terminus oriented to the ER lumen (11, 12). It has been proposed that these interactions 78 
drive the incorporation of the outer layer proteins into the transitory lipid envelope that 79 
DLPs acquire during ER membrane budding; this envelope is removed in the lumen of the 80 











































to produce the final infectious TLPs (13, 14). Although the precise mechanism of the final 82 
steps of rotavirus assembly is not well understood, it has been found that VP7 structure 83 
forms trimers on the surface of the virion in a calcium-dependent process (15–18).  84 
Due to the high complexity of rotavirus replication, many of the cellular factors and 85 
molecular mechanisms involved in this process are poorly characterized. However, it has 86 
been recently reported that the coatomer protein I (COPI)/Arf1 machinery is essential for 87 
virus replication since knocking-down by RNA interference (RNAi) the expression of some 88 
of the proteins that integrate such machinery reduces virus replication (19, 20). Also, 89 
brefeldin A (BFA), an inhibitor of the COPI/Arf1-mediated vesicular transport, 90 
significantly impairs the rotavirus progeny yield (21). COPI is a protein complex formed by 91 
seven subunits (α, β, β´, δ, ε, γ and ζ-COP) that mediates the retrograde transport of vesicles 92 
from the Golgi apparatus to the ER (22–24). Besides its canonical functions in the secretory 93 
pathway, the COPI/Arf1 machinery also may participate in the maturation of early 94 
endosomes and in recycling proteins to the plasma membrane (25, 26), as well as in the 95 
maturation of phagosomes (27, 28) and peroxisomes (29). Furthermore, multiple reports 96 
suggest that the COPI/Arf1 machinery is also involved in transport events involved in the 97 
maturation and function of lipid droplets (LDs) (30–32).  98 
In the initial step of the COPI transport, the small GTPase Arf1 (ADP-ribosylation factor 1) 99 
is activated with a GTP molecule in a process catalyzed by the guanine nucleotide 100 
exchange factor GBF1 (Golgi-specific BFA resistance factor 1) located at the cis-Golgi 101 
membrane and the intermediate ER-Golgi compartment (ERGIC) (33). The activated Arf1-102 
GTP associates with the Golgi membrane and promotes the recruitment of the preformed 103 











































of Arf1-COPI-Arf1GAP complex stimulates the binding and concentration of different 105 
cargoes located in the membrane, association that induces the bending of the membrane 106 
into a vesicle. Once completed, the vesicle buds from the membrane covered by the COPI 107 
complex proteins. Finally, the coat proteins are disassembled when the GTPase activity of 108 
Arf1 is enhanced by Arf1GAP, leading to the hydrolysis of the GTP bound to Arf1. This 109 
hydrolysis leads to the release from the membrane of Arf1, COPI, and Arf1GAP (34, 35). 110 
GBF1 belongs to a subfamily of large guanine nucleotide exchange factors (GEFs) that also 111 
includes the mammalian BIG1, and BIG2 located at the trans-Golgi network (TGN) (36). 112 
These three GEFs activate Arf1, however GBF1 may also use Arf4 and Arf5 as substrates 113 
(37–39), while BIG1 and BIG2 can catalyze the activation of Arf3, Arf5 and Arf6 (40–42). 114 
Arf activation is catalyzed by the Sec7 domain, shared by all GEFs. In addition, GBF1 115 
contains five non-catalytic domains: the N-terminal dimerization and cyclophilin binding 116 
(DCB), the homology upstream of Sec7 (HUS), and three C-terminal homology 117 
downstream of Sec7 (HDS1-3) domains (33, 36). The functions of these non-catalytic 118 
domains are not well understood, but the N-terminal DCB and HUS domains have been 119 
implicated in inter- and intra-molecular interactions important for GBF1 dimerization and 120 
its association to membranes (43, 44), while the HDS1-3 domains have been suggested to 121 
facilitate GBF1 association with membranes(45–48). 122 
In this study, we evaluated the role of the GBF1/COPI/Arf1 machinery in rotavirus 123 
replication. We showed that the catalytic activity of GBF1 is critical for virus replication by 124 
using two different pharmacological inhibitors, BFA and Golgicide A (GCA), and 125 
knocking down GBF1 expression by RNAi. We found that interfering with GBF1 activity 126 











































virus surface proteins, VP7 and VP4, which prevents the production of mature and 128 
infectious TLPs. We also showed that this restriction in the assembly of TLPs is the result 129 
of a damage in VP7 trimerization required for its assembly into DLPs. We provide 130 
evidence suggesting that the altered post-translational modification of either VP7 or NSP4 131 
in GBF1-inactivated cells is responsible for the defective formation of VP7 trimers. 132 
Altogether, our findings suggest that GBF1 activity is essential for the rotavirus outer 133 
capsid assembly by allowing the correct processing of VP7 and/or NSP4, possibly through 134 
a mechanism independent of Arf1. 135 
RESULTS 136 
Inhibition of GBF1 hinders rotavirus replication. Earlier reports have indicated that the 137 
COPI/Arf1 machinery is important for rotavirus replication (19, 20) and we characterized 138 
the effects of the pharmacological inhibitors BFA and GCA, which block the GBF1-139 
mediated activation of Arf1 required for COPI transport (34, 35, 49, 50) on the replication 140 
of rotaviruses. In these assays, MA104 cells were pretreated for 30 min with different 141 
concentrations of BFA or GCA before virus infection. The simian rhesus rotavirus (RRV) 142 
was then added to cells in the presence of the inhibitors for 1 h at 37°C. Then, the virus 143 
inoculum was removed, and fresh media containing the inhibitors were added; 12 h post 144 
infection (hpi), the total virus (from cells and media) was recovered, and the viral yield was 145 
determined. We found that treatment with BFA (at a concentration of 0.5 μg/ml or higher) 146 
reduced by more than 100-fold the viral yield (Fig 1A); this observation is in agreement 147 











































Similarly, treatment with GCA diminished viral progeny about 50-fold (Fig 1B). Cell 149 
treatment with the inhibitors did not alter cell viability at any of the concentrations tested, 150 
as determined by an LDH assay (data not shown). Moreover, the reduction of viral yield 151 
was independent of the rotavirus strain tested, since BFA also significantly inhibited the 152 
replication of SA11 (simian origin), UK (bovine origin), 69M (human origin), and YM 153 
(porcine origin) (Fig 1C). However, the extent of inhibition differed among the strains; 154 
while the replication of SA11 was reduced to a level similar to RRV (about 100-fold), that 155 
of rotavirus strains UK, 69M, and YM was reduced by about 10-fold.   156 
To determine whether GBF1 was directly involved in virus replication, we transfected 157 
MA104 cells with an siRNA to GBF1, which very efficiently knocked-down the synthesis 158 
of this protein (Fig. 1D, left), and 72 h post-transfection (hpt), cells were infected with 159 
RRV. After 12 hpi the total virus was harvested, and the viral yield was determined. 160 
Silencing the expression of GBF1 reduced the yield of viral progeny by about 70% as 161 
compared to that produced in cells transfected with control, irrelevant siRNA (Fig 1D, 162 
right). These results, together with the fact that GCA decreases RRV replication to a level 163 
similar to that observed with BFA, strongly suggest that GBF1 activity might be involved 164 
in the replication cycle of rotaviruses. 165 
BFA and GCA inhibit a post-entry stage of the virus replication cycle. To evaluate the 166 
step of the virus lifecycle affected by BFA and GCA, the drugs were added at different 167 
times post-infection to cells infected with RRV, as indicated in Fig. 2A, and at 12 hpi the 168 
total virus was recovered, and the viral yield was determined. The addition of the drugs at 0 169 
and 2 hpi decreased the viral yield by more than 90%; the inhibitory effect was less evident 170 











































60% of the viral progeny production, and at later times they showed no significant 172 
inhibitory activity (Fig 2A). The fact that the drugs showed a similar inhibitory effect when 173 
pre-incubated with cells or when added 2 hpi suggests that the inhibitors are most likely 174 
affecting the replication of RRV at a post-entry step. These findings are in agreement with 175 
the previous observation that the effect of silencing the expression of β-COP on virus 176 
replication was not relieved by transfection of RRV double-layered particles into the 177 
siRNA-treated cells (19). Of interest, the fact that the effect of the drugs seems to decline 178 
when added at 4 hpi, time at which the assembly of virus particles has already started (Fig. 179 
2B), suggests that the inhibitors could interfere with the virus assembly process. The 180 
similar effect observed for GCA and BFA supports the initial observation that the relevant 181 
target for the drugs is GBF1. 182 
BFA and GCA block the production of TLPs. To confirm that the decrease in viral yield 183 
was related to a defect in virus assembly, MA104 cells were infected with RRV in the 184 
presence of the drugs and the assembly of viral particles was analyzed by CsCl density 185 
gradients. In control conditions, two opalescent bands were observed in the gradients (Figs. 186 
3A and 3C), which were shown to correspond to TLPs and DLPs by PAGE analysis (Figs. 187 
3B and 3D). In contrast, in cells treated with BFA or GCA, a single major band that 188 
migrated at a density similar to that of DLPs was detected, and by PAGE was shown to 189 
contain particles formed exclusively by proteins VP1, VP2 and VP6 (Fig. 3B). These 190 
results indicate that the inhibitors block the assembly of the outermost protein layer, formed 191 
by VP4 and VP7, onto the correctly assembled DLPs. 192 
These results were confirmed by negative-staining electron microscopy analysis of drug-193 











































drugs, and 6 hpi cells were fixed and processed for electron microscopy. In control, 195 
untreated cells, typical electro-dense viroplasm structures were observed near the ER 196 
membrane. Furthermore, viral particles, presumably DLPs, appear to be budding into the 197 
lumen of the ER leading to the formation of membrane-enveloped particles. Many of the 198 
viral particles within the ER seem to have lost their lipid envelope and look like mature 199 
TLPs (Fig 4A). We found that neither BFA nor GCA prevented the budding of DLPs into 200 
the ER to form membrane-enveloped particles; however, the assembly pathway seems to be 201 
arrested at this point since the intermediate enveloped particles accumulated within the ER 202 
and they did not seem to mature to TLPs (Fig. 4B and 4C). It should be noted that the 203 
intermediate membrane-enveloped particles are not detected in the CsCl gradients since 204 
they most probably lose their membrane upon with trichloromonofluoromethane extraction, 205 
and are rather detected as DLPs. 206 
The electrophoretic mobility of VP7 and NSP4 is altered during the inhibition of 207 
GBF1 activity. Since it has been reported that BFA alters the electrophoretic mobility of 208 
VP7 and NSP4 (21), we decided to investigate if the effect of GCA in virus assembly was 209 
related to a modification of these viral proteins. MA104 cells were infected with RRV in 210 
the presence of the inhibitors as described above, and at 7.5 hpi, the cellular proteins were 211 
pulse-labeled with 35S-Met for 30 min and chased for 2 h. As seen in Fig. 5A, the inhibitors 212 
did not affect the synthesis of either cellular or viral proteins. However, the viral 213 
glycoproteins VP7 and NSP4 had modified electrophoretic mobility in the presence of the 214 
drugs. In treated cells, VP7 migrated slower than in control cells, while NSP4 showed 215 











































treated infected cells labeled with 3H-mannose, conditions in which only the two viral 217 
glycoproteins are labeled (Fig. 5B). 218 
To confirm that the alterations in the electrophoretic mobility of VP7 and NSP4 were due 219 
to the inhibition of GBF1, MA104 cells were transfected with the siRNA to GBF1 to 220 
silence its expression, and infected with RRV; at 7.5 hpi the cells were pulse-labeled with 221 
35S-Met as described above. As observed when the pharmacological inhibitors were used, 222 
knocking down the expression of GBF1 also caused changes in the electrophoretic mobility 223 
of VP7 and NSP4 (Fig 5C); in this case, the change was partial, most likely due to 224 
incomplete GBF1 knock down in all cells. To our knowledge GBF1 is the first identified 225 
regulatory cellular factor that affects the mobility of VP7 and NSP4. 226 
Furthermore, we also observed that the modification of the electrophoretic mobility of VP7 227 
and NSP4 was independent of the rotavirus strain, since these changes were also observed 228 
for rotavirus strains SA11, UK, 69M, and YM, after BFA treatment (data not shown). 229 
These results indicate that despite the different amino acid sequences of VP7 and NSP4 230 
among the various rotavirus strains, the lack of GBF1 activity inhibits a common 231 
posttranslational processing. 232 
Modification of the electrophoretic mobility of VP7 in the presence of BFA or GCA is 233 
not related to changes in the structure of its carbohydrate chain. It has been previously 234 
shown that the treatment of rotavirus-infected MA104 cells with BFA reduces the 235 
electrophoretic mobility of VP7, and it was proposed that this change could be related to an 236 
altered oligosaccharide chain (21). To determine if the abnormal migration of VP7 in the 237 











































characterized the effect of the drugs on the migration of the VP7 protein and replication of 239 
the mutant strain SA11-CL28, a simian rotavirus SA11 variant that lacks the N-240 
glycosylation site in VP7 and thus is non-glycosylated (51). The absence of glycosylation 241 
of this protein was confirmed by metabolically labeling the virus with 3H-mannose. NSP4, 242 
but not VP7 was labeled, as detected by PAGE and fluorography (data not shown).  243 
Similar to that observed with wild type SA11 (SA11wt), treatment of cells with BFA or 244 
GCA decreased yield of mutant SA11-CL28 virus by more than 90% (Fig. 6A). The drug 245 
treatments also reduced the electrophoretic mobility of both, the glycosylated VP7 of 246 
SA11wt and the non-glycosylated VP7 of the SA11-CL28 (Fig 6B), suggesting that the 247 
change in mobility of VP7 in cells treated with the drugs is not due to a change in 248 
glycosylation. Furthermore, by characterizing the electrophoretic mobility of a recombinant 249 
RRV VP7 protein overexpressed in MA104 cells, we show that the change observed after 250 
BFA treatment is not due to either N- or O-glycosylation or to phosphorylation (Fig. 7A-C). 251 
In addition, a recombinant RRV VP7 protein with the N-glycosylation site mutated (69-252 
NST-71 to 69-QSG-71) still showed a reduced electrophoretic mobility after treatment with 253 
BFA or GCA, confirming the results observed with the mutant SA11-CL28 virus (Fig.7D). 254 
An inefficient trimerization of VP7 may be responsible for the defective assembly of 255 
TLPs. It has been shown that in the absence of VP7 the transiently enveloped intermediate 256 
particles do not mature to infectious virus (52); it was proposed that after budding into the 257 
lumen of the ER, VP7 assembles into the DLPs excluding the lipid envelope during this 258 
process as well as NSP4, yielding the mature infectious virions (52). Since VP7 exists as 259 
trimers in the mature, infectious virus particles (17), we evaluated whether BFA and GCA 260 











































RRV in the presence of either inhibitor, and 6 hpi the cells were fixed and co-stained with 262 
an antibody to the viral nonstructural protein NSP2 that forms part of the viroplasms, and 263 
with monoclonal antibody 159 (MAb 159) to VP7, which only recognizes the trimeric form 264 
of the protein (18, 53).  265 
In rotavirus-infected, untreated cells, the trimeric isoform of VP7 was observed in the 266 
cytoplasm of infected cells, surrounding the viroplasms (Figure 8A). In contrast, in cells 267 
treated with BFA or GCA, even though the presence of NSP2 was detected, no signal of the 268 
trimeric form of VP7 was observed (Fig 8A). To verify that the lack of trimers was not due 269 
to the absence of VP7, we conducted the same assay but using mAb M60, which primarily 270 
recognizes the monomeric, non-virion-associated form of VP7 (18, 53). In the absence of 271 
inhibitors, the monomeric form of VP7 showed a reticular pattern distributed across the cell 272 
cytoplasm, with some of the protein surrounding viroplasms (Figure 8A). Treatment with 273 
the inhibitors did not abolish the signal of the VP7 monomers, although the distribution of 274 
the protein changed to a punctate pattern (Fig. 8A). Taken together, the treatment with BFA 275 
or GCA prevents the formation of VP7 trimers. Of interest, the block in the trimerization of 276 
VP7 seems to be independent of alterations in its glycosylation pattern, since BFA also 277 
inhibited the trimerization of the VP7 protein of SA11wt and SA11-CL28 viruses without 278 
apparently altering the intracellular levels of the monomeric form of the protein (Fig 8B 279 
and 8C). 280 
We also found that knocking down the expression of GBF1 abolished the trimerization of 281 
VP7 (Fig. 9); similar to the experiments with the pharmacological inhibitors, the trimeric 282 
form of VP7 (MAb 159) was detected at 6 hpi in the majority of the infected cells 283 











































GBF1, the trimeric form of VP7 could not be detected, even though the cells were positive 285 
for NSP2. However, as described above, the absence of trimers was not due to a deficient 286 
synthesis of VP7, since in GBF1-silenced cells the monomeric form of VP7 (detected by 287 
MAb M60), was observed in most cells (Fig 9). 288 
NSP4 is involved in VP7 trimerization. To explore if the lack of trimerization of VP7 289 
could be related to the change in electrophoretic mobility of NSP4, the expression of NSP4 290 
was silenced by RNAi in MA104 cells stably expressing the NSP5 protein fused to 291 
EGFP(54), and the presence of NSP4 as well as the trimeric or monomeric forms of VP7 292 
were determined in infected cells with specific antibodies. As can be observed in Fig 10 293 
(upper panels), cells transfected with an irrelevant siRNA contained the trimeric form of 294 
VP7, as detected with Mab159. In contrast, the cells depleted of NSP4 did not show the 295 
trimeric form of VP7, even though they were infected as judged by the presence of the 296 
viroplasms labeled with NSP5-EGFP. Similar to the previous experiments, the absence of 297 
trimers was not due to a deficient synthesis of VP7, since the monomeric form of VP7 298 
(detected with MAb M60) was observed in NSP4-silenced cells (Fig 10, lower panels). 299 
Moreover, as previously reported (52), knocking down the expression of NSP4 induced a 300 
reduction in the size of viroplasms (Fig 10). This result is consisitent with a previous report 301 
showing that NSP4 might stimulate the assembly of VP7 (55). 302 
To further explore whether the trimerization of VP7 depends on the presence of NSP4, 303 
Hek293 cells expressing constitutively the T7 polymerase (T7pol) (56) were co-transfected 304 
with plasmids D1R and D12L encoding the two subunits of the vaccinia virus capping 305 
enzyme, which efficiently caps the T7pol RNA polymerase transcripts in the cytoplasm 306 











































with both plasmids simultaneously. At 24 hpt the cells were fixed and immunostained for 308 
NSP4 and VP7. In cells in which the plasmid for VP7 was transfected alone, the 309 
monomeric form of VP7 (MAb M60) was clearly visible, whereas there was no signal with 310 
MAb 159 that detect the trimer; in contrast, when the plasmids for VP7 and NSP4 were co-311 
transfected, trimeric VP7 was detected and colocalized with NSP4 (Fig. 11). These results 312 
confirm that the presence of NSP4 is relevant (directly or indirectly) for the correct 313 
assembly of VP7 into trimers. 314 
Distinct domains of GBF1 are essential for rotavirus replication. To explore the 315 
potential involvement of the different GBF1 domains in rotavirus progeny production, we 316 
compared the replication of the virus in Hek293 cells transfected with GBF1 construct 317 
containing the A795E mutation (GBF1/795) that confers resistance to BFA (47, 58), or 318 
with a series of mutant GBF1/795 proteins (Fig 12A) (59).  319 
For these assays, Hek293 cells were transfected with the different constructs, and at 24 hpt, 320 
the cells were infected with RRV. At 12 hpi the total virus was harvested, and the viral 321 
yield was determined. Figure 12B shows that the full-length GBF1/795 was able to rescue 322 
the replication of rotavirus in the presence of BFA. In addition, the GBF1/795/1531t was 323 
able to rescue, albeit partially, viral replication. In contrast, none of the other GBF1 mutants 324 
could support virus replication. These findings indicate that the C-terminal domain of 325 
GBF1 is not absolutely critical for replication of the virus, while all other domains of GBF1 326 
are required.  327 
We also tested a GBF1/795 mutant that encoded a protein with an amino acid substitution 328 











































with a construct  in which the C-terminal loop of Sec7 domain (EIVMPEE at positions 330 
883–889) was disrupted by the substitution of 7 alanines, producing a GBF1 protein 331 
defective in Arf biding and activation (GBF1/795/7A)(61)(Fig 12A). Both, the catalytic 332 
inactive GBF1/795/E794K and GBF1/795/7A mutants were unable to support rotavirus 333 
replication in the presence of BFA, suggesting that the ability of GBF1 to activate Arf is 334 
important for virus progeny production. All GBF1/795 constructs had been shown to be 335 
expressed to a similar level, as determined by western blot (58, 59) 336 
The previous results suggested that Arf1 activation might be important for rotavirus 337 
replication. This observation was tested by transfecting MA104 cells with an siRNA to 338 
Arf1, which very efficiently knocked-down the synthesis of the protein (Fig. 12C, left), and 339 
at 72 hpt, infecting the cells with RRV. At 12 hpi the total virus was harvested, and the 340 
viral yield was determined. Silencing the expression of Arf1 did not affect the yield of viral 341 
progeny as compared to that produced in cells transfected with a control, irrelevant siRNA 342 
(Fig 12C, right). These results suggest that GBF1 catalytic activity is essential for rotavirus 343 
replication, but the activation of Arf1 is not required.  344 
DISCUSSION 345 
Eukaryotic cells use elaborated systems to control the traffic of proteins between different 346 
organelles. The COPI/Arf1 machinery has been shown to participate in several of these 347 
transport processes, including its recent involvement in maturation and function of lipid 348 
droplets (LDs) (30–32). The COPI/Arf1 complex is also emerging as an important cellular 349 
factor for the replication of several RNA viruses. In the case of influenza (62, 63) and 350 











































their entry process. Moreover, for VSV as well as for hepatitis C virus (66–68), mouse 352 
hepatitis coronavirus (69), chikungunya virus (70), poliovirus (58, 59, 71), coxsackievirus 353 
(72) and classical swine fever virus (73), COPI/Arf1 has been shown to be necessary for 354 
genome replication as well as for viral protein expression. COPI/Arf1 has also been shown 355 
to be critical for viral particle assembly of influenza and the Chandipura virus (63, 74). The 356 
specific mechanism through which COPI/Arf1 participate in these processes has not been 357 
characterized; however, GBF1, involved in the first step of the COPI/Arf1 transport 358 
process, has been shown to play an important role for the replication of some of these 359 
viruses. For example, for enteroviruses, the recruitment of GBF1 to the membranous 360 
structures where the viral RNA synthesis takes place, mediated by the viral 3A protein, is 361 
crucial for genome replication. Moreover, in this case, the function of GBF1 appears 362 
independent of Arf1 activation (58, 75).  363 
In this work, we studied the effect of inhibiting the function of the GBF1/COPI/Arf1 364 
machinery on the replication of rotavirus using the pharmacological inhibitors BFA and 365 
GCA. We found that both inhibitors induced a significant reduction in the progeny 366 
production of different rotavirus strains belonging to different G and P serotypes, indicating 367 
that these drugs block a common pathway for all these viruses.  368 
GCA inhibits the COPI/Arf1 machinery activity by selectively inhibiting GBF1; BFA, on 369 
the other hand, also inhibits BIG1 and BIG2 (49, 76). BIG1 and BIG2 are involved in 370 
vesicular traffic of clathrin-coated vesicles at the TGN (77–79). Our observations suggest 371 
that GBF1, and not the BIGs, is the factor targeted by BFA and GCA that causes the 372 
reduction of rotavirus replication. The importance of GBF1 was confirmed since knocking 373 











































In line with previous observations, we found that in cells treated with BFA and infected 375 
with RRV, the electrophoretic mobility of both VP7 and NSP4 was modified. Although it 376 
has been clearly demonstrated that the modification of NSP4 is due to oligosaccharide 377 
processing (21), the modification of VP7 is currently unknown. Since no infectious virus 378 
was produced under those conditions, it was also proposed that the altered oligosaccharide 379 
processing of VP7 was responsible for the defective assembly of viral particles (21). Our 380 
results indicate that for VP7, the altered electrophoretic mobility is independent of its 381 
glycosylation pattern, since both the non-glycosylated VP7 of the SA11-CL28 virus and a 382 
recombinant VP7 protein with the N-glycosylation site mutated showed an altered mobility 383 
in the presence of the drugs. These results are in agreement with previous findings showing 384 
that cell treatment with both BFA and tunicamycin, an inhibitor of N-glycosylation (80), 385 
produce a VP7 protein with altered mobility (21). In addition, the changes in VP7 mobility 386 
were not due to O-glycosylation nor phosphorylation of the protein. The possibility that the 387 
drugs block the removal of the signal peptide of VP7 (81) remains to be explored. 388 
The observation that silencing the expression of GBF1 induced changes in the mobility of 389 
both VP7 and NSP4 suggests that the activity of this cellular factor is essential for the 390 
correct processing of both proteins. Taking into consideration that GBF1 functions at the 391 
ER-Golgi interface and that rotaviruses mature in the ER, it seems likely that Golgi-ER 392 
transport is the relevant process required for the correct maturation of rotavirus infectious 393 
particles. However, considering that LDs have been proposed to play a significant role in 394 
the replication cycle of rotaviruses, it remains possible that the protein transport between 395 
the ER membrane and LDs is needed for the correct processing of both VP7 (glycosylation 396 











































Since the assembly of VP7 onto DLPs has been suggested to require VP7 trimerization, the 398 
effect of the drugs on trimerization was evaluated. We found that VP7 was not able to 399 
trimerize (as judged by the lack of recognition of VP7 by MAb 159, which specifically 400 
interacts with the trimeric but not with the monomeric form of the protein (18)) in the 401 
presence of the inhibitors or in cells where the GBF1 expression was silenced,. Our 402 
findings differ from previous observations that BFA has minimal effects on the antigenicity 403 
of VP7 (as judged by recognition by MAb 159 in immunoperoxidase staining (21)). The 404 
reason for this discrepancy might be the methods employed for the detection of the 405 
MAb159 signal, immunofluorescence in our work versus immunoperoxidase staining in the 406 
previous report (21), which may have different sensitivity. 407 
The drug-induced modification of VP7 could, in principle, prevent its trimerization. 408 
However, it is also possible that the modification of NSP4 could impair VP7 trimerization. 409 
Even if the NSP4 function as a receptor in the ER membrane is not affected by the drug 410 
treatments, it is plausible that the modifications in its glycosylation pattern could affect its 411 
role in facilitating (directly or indirectly) the trimerization of VP7 during the removal of the 412 
envelope in the last step virus assembly. The role of NSP4 in the trimerization of VP7 is 413 
supported by earlier observation where tunicamycin, an inhibitor of N-glycosylation, 414 
restricts the maturation of enveloped particles of SA11-CL28 by inhibiting the 415 
glycosylation of NSP4 (82). On the other hand, it is known that the stability of the VP7 416 
trimers depends on the presence of calcium (Ca2+) (15, 18),  suggesting that alteration in 417 
the calcium homeostasis of the cell could be responsible for the lack of the outer layer 418 
assembly of rotaviruses. It has been shown that rotavirus infection increases the Ca2+ 419 











































concentration, but that BFA inhibits this enhancement (83). Thus, it cannot be excluded that 421 
the deficient trimerization of VP7 is due to altered calcium homeostasis. 422 
The multidomain structure of GBF1 allows it to engage in numerous interactions with other 423 
cellular, as well as viral proteins (33, 59, 75). To gain information about the importance of 424 
the different domains of GBF1 in rotavirus replication, we tested the ability of different 425 
truncated forms of GBF1 to support the production of virus progeny in the presence of 426 
BFA. A recombinant full length GBF1 carrying a mutation in the Sec7 domain that renders 427 
the protein resistant to the inhibitory action of BFA (GBF1/795) was able to rescue virus 428 
replication, as did a mutant GFB1 protein lacking the C-terminal HDS3 domain (albeit less 429 
well), suggesting that HDS3 is dispensable for viral replication. Although the precise 430 
function of the HDS3 is unknown, it appears essential for GBF1 membrane association, 431 
since the GBF1/795/1531t mutant is inefficiently targeted to Golgi, remaining 432 
predominantly cytosolic, albeit some fraction of this mutant is able to associate the 433 
membranes (unpublished results). It possible that the small fraction of the GBF1/795/1531t 434 
mutant that is able to associate to membranes is capable to activate sufficient Arf molecules 435 
to allow the lifecycle of the virus to proceed. 436 
The catalytically inactive mutants of GBF1 (GBF1/795/E794K and GBF1/795/7A) failed to 437 
support replication of the virus, suggesting that GBF1 activity is essential for rotavirus 438 
progeny production. Although the catalytic activity of GBF1 appears essential for rotavirus 439 
replication, we found that the activation of Arf1 is not required, since knocking- down the 440 
expression of this factor does not affect the production of infectious virus. Thus, it is likely 441 











































Arf5 (Claude et al., 1999; Niu et al., 2005; Szul et al., 2005) that could compensate for the 443 
reduced level of Arf1.   444 
Previous findings reported that the most N-terminal 37 amino acids of GBF1 are important 445 
for the replication of coxsackie B3 virus and poliovirus (58, 59, 75, 84) by targeting the 3A 446 
protein to membranes where the virus replication complexes will assemble. Similarly, we 447 
showed that this deletion renders GBF1 unable to support rotavirus replication in the 448 
presence of BFA. It is possible that this 37 amino acid stretch could bind a rotaviral protein, 449 
although it may also interact with a cellular factor to support virus replication. In fact, it has 450 
been reported that Rab1b is able to interact with the N-terminus of GBF1 to modulate 451 
GBF1 function in the secretory pathway (85). Further experiments will have to be carried 452 
out to explore more in detail the mechanism through which GBF1 supports rotavirus 453 
replication. 454 
MATERIALS AND METHODS 455 
Cell and viruses. MA104 rhesus monkey kidney epithelial cells (ATCC), and Hek293 456 
human embryonic cells stably expressing phage T7 polymerase, kindly provided by Dr. 457 
Carlos Sandoval Jaime (Instituto de Biotecnología, Cuernavaca, Mexico) (56), were grown 458 
in Dulbecco's Modified Eagle Medium-Reduced Serum (DMEM-RS) (Thermo Scientific 459 
HyClone, Logan, UT) supplemented with 5% heat-inactivated fetal bovine serum (FBS) 460 
(Biowest, Kansas City, MO) at 37°C in a 5% CO2 atmosphere. Simian (RRV, G3P5B[3]; 461 
SA11, G3P5B[2]; and SA11-CL28, G3P5B[2]), bovine (UK, G6P7[5]), porcine (YM, 462 
G11P9[7]), and human (69M, G8P4[10]) rotaviruses were propagated in MA104. Briefly, 463 











































USA) for 30 min at 37°C. Afterwards, the activated viruses were adsorbed to the cells for 1 465 
h at 37°C. The unbound virus was removed, and the cells were incubated for 16 h at 37 °C. 466 
Finally, the cells were lysed by two cycles of freeze-thawing and the cell debris were 467 
removed by centrifugation. The resulting viral lysate was stored at -70°C. 468 
Reagents and antibodies. Brefeldin A (B7651, Sigma-Aldrich, St. Louis, MO, USA) was 469 
dissolved in ethanol, and Golgicide A (345862, Calbiochem, San Diego, CA, USA) was 470 
dissolved in dimethyl sulfoxide (DMSO). Monoclonal antibodies (MAbs) to the monomeric 471 
(M60) and trimeric (MAb159) forms of VP7 (53) were kindly provided by H. B. Greenberg 472 
(Stanford University, Stanford, USA). The rabbit anti-rotavirus polyclonal serum raised 473 
against purified TLPs(52), the rabbit polyclonal sera to NSP2(86) and NSP4(87), as well as 474 
the rabbit polyclonal sera to human vimentin(52), were produced in our laboratory. Mouse 475 
monoclonal antibody to GBF1 was purchased from BD Transduction Laboratories (San 476 
Jose, CA, USA). Goat anti-mouse Alexa-488, goat anti-mouse Alexa-647, and goat anti-477 
rabbit Alexa-568-conjugated used as secondary antibodies were obtained from Molecular 478 
Probes (Eugene, OR, USA). Horseradish peroxidase-conjugated goat anti-rabbit and anti-479 
mouse antibodies were purchased from PerkinElmer Life Sciences (Boston, MA, USA).  480 
SiRNAs and plasmids. The small interfering RNA (siRNA) to GBF1, Arf1 and the control 481 
siGENOME nontargeting siRNA were purchased from GE Healthcare Dharmacon 482 
(Lafayette, CO, USA). For the construction of pcDNA3-VP7 and pcDNA3-NSP4 plasmids, 483 
the VP7 and NSP4 genes were cloned from extracts of RRV- and SA11-infected cells, 484 
respectively. The cDNA was obtained by RT-PCR using specific primers for amplifying 485 
the open reading frame (ORF) of VP7 or NSP4 and cloned into pcDNA3 (Life 486 











































plasmid was obtained by site-direct mutagenesis of the glycosylated VP7 of RRV. Vaccinia 488 
virus capping enzyme expression plasmids, pCAG-D1R and pCAG-D12L (Addgene 489 
plasmids # 89160 and # 89161, respectively) were a gift from T. Kobayashi (Osaka 490 
University, Osaka, Japan). All GBF1 (UniProtKB: Q92538) truncations were introduced 491 
into the backbone of Venus tagged-GBF1/A795E (described in 57) using QuickChange XL 492 
site-directed mutagenesis kit from Agilent Technology. The GBF1/795/E794K construct 493 
was generated by introducing the A795E mutation into GFP-tagged GBF1 E794K-GFP 494 
construct (described in 59). Following PCR, constructs were transformed into XL 10 gold 495 
cells. DNA was isolated and all mutations were confirmed by sequencing. The 496 
GBF1/795/7A construct has been described (61). The GBF11/795/∆37 construct has been 497 
described (58). 498 
Immunoperoxidase assay. MA104 cells were grown in 96-well plates to confluence. The 499 
cells were then infected with two-fold serial dilutions of the different viral lysates for 1h at 500 
37°C. After this time, the non-adsorbed virus was removed, and the cells were incubated at 501 
37°C for 16 h. Afterwards, the cells were fixed with 80% acetone in phosphate-buffered 502 
saline (PBS) for 30 min at room temperature and then washed twice with PBS. The fixed 503 
monolayers were then incubated with a rabbit anti-rotavirus polyclonal serum, followed by 504 
incubation with a secondary anti-rabbit antibody conjugated with horseradish peroxidase. 505 
Finally, the cells were washed twice with PBS and stained with a solution of 1 mg/ml of 506 
carbazole (AEC) in sodium acetate buffer (50 mM, pH 5) with 0.04% H2O2. The reaction 507 
was stopped by washing in tap water, and the infectious focus forming units were counted 508 











































Transfection of siRNAs and plasmids. Transfection of siRNAs into MA104 cells was 510 
performed with Oligofectamine reagent (Invitrogen, Carlsbad, CA, USA) in 48-well plates 511 
using a reverse transfection method as described previously (88). Plasmids were transfected 512 
either into MA014 cells or Hek293 cells constitutively expressing the T7 polymerase, using 513 
Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 514 
instructions. 515 
Enrichment of viral particles. RRV (at an MOI of 5) was adsorbed to MA104 cells for 1 h 516 
at 4°C to allow the virus to bind to the cells. The unbound virus was removed, and the cells 517 
were incubated at 37 °C to allow the infection to proceed. At different times post-infection 518 
cells were washed with EGTA (3 mM) for 5s to release any viral particles that remained 519 
bound to the cell surface, and the cells were lysed by freeze-thawing. Viral lysates were 520 
centrifuged at 105,000 x g for 1h at 4°C in a 45Ti rotor using a Beckman ultracentrifuge 521 
(OptimaL-90). The supernatant was discarded and the viral particles in the pellet were 522 
resuspended in 4 ml TNC buffer (10 mM Tris, pH7.5, 140 mM NaCl, 10 mM CaCl2), 523 
extracted with trichloromonofluoromethane (Genetron, CYDSA 11, Mexico City, Mexico) 524 
and placed on top of a 1 ml 40% sucrose cushion in TNC. The samples were centrifuged at 525 
195,000 x g for 2 h at 4°C in a SW55Ti rotor. Finally, the resulting pellets containing the 526 
semi-purified viral particles were dissolved in TNC and analyzed by SDS-PAGE.  527 
Isopycnic gradient. MA104 cells were infected with RRV at an MOI of 5 in the presence 528 
of either 0.5 µg/ml BFA or 10µM GCA, and at 12 hpi the cells were lysed by freeze-529 
thawing. The cell lysate was extracted with trichloromonofluoromethane as described 530 
above, and the aqueous phase was mixed with 2.2 g of CsCl and TNC buffer up to 5 ml. 531 











































Finally, the opalescent bands corresponding to TLPs and DLPs were collected by puncture 533 
with a syringe and stored at 4°C. Before use, the viral particles were desalted in a Sephadex 534 
G25 spin column. 535 
Transmission electron microscopy. MA104 cells were seeded onto sapphire discs and 536 
infected with RRV an MOI of 250 viroplasm forming units (VFU)/ml in the presence of 0.5 537 
µg/ml BFA or 10µM GCA. At 6 hpi the cells were fixed with 2.5% glutaraldehyde in 100 538 
mM Na/K-phosphate buffer, pH 7.4 for 1 h at 4˚C and kept in 100 mM Na/K-phosphate 539 
buffer overnight at 4˚C. Afterwards, samples were post-fixed in 1% osmium tetroxide in 540 
100 mM Na/K-phosphate buffer for 1 h at 4˚C, dehydrated in a graded ethanol series 541 
starting at 70% followed by two changes in acetone and embedded in Epon. Ultrathin 542 
sections (60-80 nm) were cut and stained with uranyl acetate and lead citrate. Images were 543 
acquired using a transmission electron microscope (CM12, Philips, Eindhoven, The 544 
Netherlands) equipped with a CCD camera (Ultrascan 1000, Gatan, Pleasanton, CA, USA) 545 
at an acceleration of 100kV and processed using ImageJ version 2.0.0-rc-69/1.52i (Creative 546 
Common, http://imageJ.net/contributors). 547 
Metabolic labeling of proteins. MA104 cells were pre-treated with BFA (0.5 µg/ml) or 548 
GCA (10 µM) for 30 min. Afterwards, the cells were mock-infected or infected with RRV 549 
(MOI of 5) in the presence of inhibitors for 1h. At the end of the adsorption period, the cells 550 
were washed, and fresh media containing the drugs were added. At 7 hpi, the cells were 551 
starved for 30 min in the methionine-free medium before pulse-labeling with 25 µCi/ml of 552 
Easy Tag Express 35S labeling mix (Perkin Elmer, Shelton, CT, USA) for 30 min. At 8 hpi, 553 











































before lysis in Laemmli sample buffer at 10 hpi. The radiolabeled proteins were resolved in 555 
a 10% SDS-PAGE, followed by autoradiography.  556 
For 3H-mannose radiolabeling, cells were treated and infected as described above. At 6 hpi 557 
the cells were starved in a glucose-free medium for 30 min followed by labeling with 200 558 
µCi/ml of mannose-D-[2-3H(N)] (Perkin Elmer, Shelton, CT) for 1.5 h. At 8 hpi, the 3H-559 
labelling medium was removed, and the cells were incubated in complete medium before 560 
lysis in Laemmli sample buffer at 10 hpi. The radiolabeled proteins were resolved by 10% 561 
SDS-PAGE, followed by fluorography. 562 
Western blot analysis. Proteins in cell lysates were separated in a SDS-PAGE and 563 
transferred to Immobilon NC (Millipore Merck, Darmstadt, Germany) membranes. The 564 
membranes were blocked with 5% nonfat dry milk in PBS for 1 h at room temperature and 565 
then incubated with primary antibodies diluted in PBS containing 0.1% nonfat dry milk. 566 
The membranes were then incubated with the corresponding secondary antibody 567 
conjugated to horseradish peroxidase. The peroxidase activity was developed using the 568 
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer) according to the 569 
manufacturer’s instructions. The blots were also probed with an anti-vimentin antibody, 570 
which was used as a loading control. 571 
Endoglycosidases and phosphatase treatments. The pcDNA3-VP7 plasmid was 572 
transfected in MA104 cells; BFA or GCA (5 µg/ml) were added at 1 hpt and the cells were 573 
lysed (7.6% SDS, 125 mM TrisHCl, pH 6.8) at 18 hpt. Cell extracts underwent treatment 574 











































Technologies, Carlsbad, CA, USA): PNGaseF (Peptide-N-Glycosidase F), EndoH (endo-β-576 
N-acetylglucosaminidase-H), a Protein Deglycosylation Mix, and  λ-phospatase. 577 
Immunofluorescence. MA104 cells grown on glass coverslips were pre-treated with BFA 578 
(0.5 µg/ml) or GCA (10 µM) for 30 min and then infected with rotavirus at an MOI of 1. 579 
Six hpi, cells were fixed with 2% paraformaldehyde in PBS for 20 min at room 580 
temperature. After this time, the cells were washed four times with 50 mM NH4Cl in PBS 581 
and permeabilized by incubation with 0.5% Triton X-100 for 15 min at room temperature. 582 
The coverslips were incubated in blocking buffer (1% bovine serum albumin) for 1h at 583 
room temperature (RT) and then with primary antibodies diluted in blocking buffer 584 
overnight at 4°C. The cells were then washed five times and incubated with the Alexa-585 
labeled secondary antibodies in blocking buffer for 1 h at RT. Finally, cell nuclei were 586 
stained with 30 nM DAPI (4′,6-diamidino-2-phenylindole, Invitrogen, Eugene, OR, USA) 587 
for 5 min and the coverslips were mounted onto glass slides with CitiFluor AF1 antifading 588 
(Electron Microscopy Sciences, Emsdiasum, Hatfield Penn). Images were acquired with an 589 
inverted 3I spinning disk confocal microscope (Zeiss Observer Z.1) coupled to a digital 590 
EMCCD Andor Ixon (512x512 pixels) and processed using Fiji ImageJ 1.52n(89).   591 
Statistical analysis. Statistical significance was evaluated by the Mann–Whitney–592 
Wilcoxon test using GraphPad Prism 8.0.2. (GraphPad Software Inc.). The homogeneity of 593 
variances was confirmed by a Fligner Killeen test using R 3.6.0. 594 
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FIG. 1. Inhibition of COPI/Arf1 activity reduces the production of viral progeny. MA104 871 
cells were pre-treated for 30 min with BFA (A) or GCA (B) at the indicated concentrations. 872 
Treated cells were infected with RRV at an MOI of 5 in the presence of the inhibitors for 873 
1h, the unbound virus was removed, and fresh media containing the drugs was added. At 12 874 
hpi the total virus obtained from cells and media were harvested, and the viral titer was 875 
determined by an immunoperoxidase assay. The arithmetic means ± standard deviations 876 
from three independent experiments performed in duplicate are shown. (C) MA104 cells 877 
were infected with the indicated rotavirus strains (MOI of 5) in the presence of BFA 878 
(0.5µg/ml), and the viral titer (ffu/ml) of the total virus was determined by an 879 
immunoperoxidase assay. The arithmetic means ± standard deviations from two 880 
independent experiments performed in duplicate are shown. (D) MA104 cells were 881 
transfected with a siRNA to GBF1. Left panel, representative western blot analysis of cells 882 
transfected with the indicated siRNA. The expression of GBF1 was detected with a specific 883 
antibody. Vimentin (Vim) was used as a loading control. Right panel, at 72 hpt cells 884 
transfected with either a scrambled or GBF1 siRNAs were infected with RRV (MOI=5). At 885 
12 hpi, the total virus from cells and media was collected and the viral titer was determined. 886 
Data represent the percentages of virus progeny, where the cells transfected with an 887 
irrelevant siRNA (Irre), correspond to 100% infectivity. The arithmetic means ± standard 888 
deviations from three independent experiments performed in duplicate are shown. 889 
*=P<0.05, and  **=P<0.01. 890 
FIG. 2. BFA and GCA inhibit rotavirus replication at a post-entry step. (A) MA104 cells 891 
were infected with RRV (MOI=5) at 37 °C for 1h. Unbound virus was removed, and 0.5 892 











































the total virus obtained from cells and media was recovered, and the viral titer was 894 
determined. Cells Data represent the percentage of the virus progeny obtained from 895 
untreated cells that correspond to 100% infectivity. The arithmetic means ± standard 896 
deviations from two independent experiments performed in duplicate are shown. 897 
*=P<0.05,. (B) Representative gel electrophoresis analysis of RRV particles produced at 898 
different times post-infection. MA104 cells were infected with RRV (MOI=5) in the 899 
absence of the inhibitors for 1 h at 37°C. Unbound virus was removed and fresh media was 900 
added. At the indicated times post-infection the virus was semi-purified as described in 901 
Materials and Methods (see “Enrichment of viral particles” section). The same proportion 902 
of each sample was loaded onto the gel, which was silver stained. The migration pattern of 903 
the viral structural proteins is indicated (right).  904 
FIG. 3. BFA and GCA block the production of TLPs. (A) Isopycnic CsCl gradients of viral 905 
particles assembled in the absence or presence of 0.5µg/ml BFA (A) or 10µM GCA (C). 906 
(B) and (D) Gel electrophoresis analysis of the viral proteins in the bands detected in the 907 
isopycnic gradients shown in panels A and C. The same proportion of each collected band 908 
was loaded onto the gel, which was silver stained. The migration of the viral structural 909 
proteins in the gels is indicated (right). 910 
FIG. 4. BFA and GCA do not block the budding of rotavirus DLPs into the ER. MA104 911 
cells untreated (A) or treated with 0.5µg/ml BFA (B) or 10µM GCA (C) were infected with 912 
RRV at 250 viroplasm forming units per cell. At 6 hpi, the cells were fixed and processed 913 
for transmission electron microscopy. The black arrowheads indicate the swollen vesicles 914 
of the endoplasmtic reticulum observed in the presence of BFA or GCA. The open 915 











































Viroplasm; Nu, nucleus; m, mitochondrion; AP, autophagosome; mt, microtubules; ER, 917 
endoplasmatic reticulum; and GC, Golgi complex. Bar is 500 nm. 918 
FIG. 5. Inhibition of the GBF1 activity changes the electrophoretic mobility of VP7 and 919 
NSP4. (A) Autoradiography of mock infected or infected lysates (RRV, MOI of 5) in the 920 
presence of BFA (0.5µg/ml) or GCA (10µM). At 7.5 hpi, the cells were pulse-labeled with 921 
25 µCi/ml of 35S-Met/Cys for 30 min and harvested at 10 hpi. (B) Fluorography of infected 922 
lysates in the presence of BFA (0.5µg/ml) or GCA (10µM). At 6.5 hpi, the cells were 923 
radiolabeled with 200 µCi/ml of 3H-mannose for 1.5 h and harvested at 10 hpi. (C) 924 
Autoradiography of lysates transfected with the indicated siRNA and mock-infected or 925 
infected with RRV (MOI=5). At 7.5 hpi, the cells were pulse-labeled with 25 µCi/ml of 35S-926 
Met/Cys. The migration pattern of the viral structural and non-structural proteins in the gels 927 
is indicated (right). 928 
FIG. 6. The alteration of the electrophoretic mobility of VP7 in the presence of BFA or 929 
GCA is not related to modified glycosylation. (A) MA104 cells were pre-treated for 30 min 930 
with BFA (0.5 µg/ml) or GCA (10 µM), and then, infected with wild type SA11 (SA11wt) 931 
or the mutant SA11-CL28 strain, both at an MOI of 5, in the presence of inhibitors for 1 h. 932 
Unbound virus was removed, and fresh media containing BFA or GCA was added. At 12 933 
hpi, the cells were harvested, and the viral titer was determined. Data represent the virus 934 
progeny relative to untreated cells. The arithmetic means ± standard deviations from two 935 
independent experiments performed in duplicate are shown. *=P<0.05. (B) Representative 936 
western blot analysis of proteins from untreated (control), BFA- or GCA-treated cells 937 
infected with SA11wt or SA11-CL28 at 8hpi. Expression of structural viral proteins were 938 











































(Vim) was used as a loading control. The migration pattern of the viral structural proteins in 940 
the gels is indicated (right). The asterisks mark the position of the slow-migrating VP7 941 
protein.   942 
Fig. 7. BFA- and GCA-induced modification of VP7 electrophoretic mobility is related 943 
neither to N-/O-glycosylation nor to phosphorylation. MA104 cells were transfected with a 944 
plasmid coding for the VP7 protein of RRV and treated with BFA or GCA (5 µg/ml) at 1 945 
hpt. At 18 hpt the cells were lysed, and the lysate underwent treatment with either of the 946 
following enzymes: (A) PNGaseF (Peptide-N-Glycosidase F), which removes almost all 947 
types of N-linked (Asn-linked) glycosylation or EndoH (endo-β-N-acetylglucosaminidase-948 
H), which removes only high mannose and some hybrid types of N-linked carbohydrates; 949 
(B) a protein deglycosylation mix, which in addition to all N-linked glycans removes many 950 
common O-linked glycans; (C) λ-phospatase, a protein phosphatase with activity towards 951 
phosphorylated serine, threonine and tyrosine residues. The figure shows a representative 952 
western blot of the cell extracts incubated with the enzymes indicated. Expression of the 953 
VP7 protein was detected with a specific antibody. The glycosylated (gVP7) and 954 
deglycosylated (VP7) forms of VP7 are indicated.  Tubulin (TUB) was used as loading 955 
control. (D) Representative western blot of MA104 cells expressing a recombinant RRV 956 
VP7 protein with the N-glycosylation site mutated (69-NST-71 to 69-QSG-71); BFA (2.5 957 
µg/ml) was added at 1 hpt and the cells were lysed at 18 hpt. The expression of non-958 
glycosylated VP7 was detected with a specific antibody. 959 
FIG. 8. BFA and GCA inhibit the trimerization of the glycosylated and non-glycosylated 960 
forms of VP7. Immunofluorescence of MA104 cells infected with RRV (A), SA11wt (B), 961 











































(10 μM). At 6 hpi, the cells were fixed and co-immunostained with either antibodies against 963 
NSP2 (red) and VP7 trimers (MAb159, green) (upper row) or NSP2 (red) and VP7 964 
monomers (M60, green) (lower row). The nuclei (blue) were stained with DAPI. The open 965 
box corresponds to amplified images at the right column of each image. Scale bar is 10 µm. 966 
FIG. 9. Silencing the expression of GBF1 blocks VP7 trimerization. Immunofluorescence 967 
of MA104 cells transfected with the indicated siRNA and at 72 hpt, cells were infected with 968 
RRV (MOI, 3). At 6 hpi, the cells were fixed and co-immunostained with antibodies 969 
against either NSP2 (red) and VP7 trimers (Mab159, green) (upper panel) or NSP2 (red) 970 
and VP7 monomers (M60, green) (lower panel). The cells nuclei (blue) were stained with 971 
DAPI. The open box corresponds to magnified images shown at right. Scale bar is 10 µm. 972 
FIG. 10. Silencing the expression of NSP4 inhibits the trimerization of VP7. 973 
Immunofluorescence of MA104 cells stably expressin NSP5-EFGP (magenta), which were 974 
transfected with the indicated siRNA, and infected with RRV (MOI, 3) at 72 h post-975 
transfection. At 6 hpi, cells were fixed and co-immunostained with antibodies against either 976 
NSP4 (red) and VP7 trimers (MAb159, green) (upper row) or NSP4 (red) and VP7 977 
monomers (M60, green) (lower row). Cells nuclei (blue) were stained with DAPI.. Scale 978 
bar is 10 µm.    979 
FIG. 11. NSP4 facilitates the VP7 trimerization. Immunofluorescence of Hek293-T7 RNA 980 
polymerase cells co-transfected with the VV capping enzyme expression plasmids (D1R 981 
and D12L) and either a plasmid encoding for non-glycosylated VP7, NSP4, or a 982 
combination of both plasmids. At 24 hpt, the cells were fixed and co-immunostained with 983 











































and VP7 trimers (MAb159, green). The cells nuclei (blue) were stained with DAPI. Scale 985 
bar is 10 µm. 986 
Fig 12. GBF1 catalytic activity but not Arf1 activation is essential for rotavirus replication. 987 
(A) Schematic map of GBF1 domain organization and of truncated mutants used in this 988 
study, in which the amino acid substitutions are indicated. Numbers in parenthesis indicate 989 
GBF1 amino acids. (B) Hek293 cells were transfected with the different GBF1 mutant 990 
plasmids, and at 24 hpt cells were pre-treated for 30 min with BFA (0.5 µg/ml), and then, 991 
infected with RRV at an MOI of 5, in the presence of BFA for 1 h. Unbound virus was 992 
removed, and fresh media containing BFA was added. At 12 hpi, the cells were harvested, 993 
and the viral titer was determined. Data represent the virus progeny relative to untreated 994 
cells. The arithmetic means ± standard deviations from three independent experiments 995 
performed in duplicate are shown. *=P<0.05. (C) MA104 cells were transfected with a 996 
siRNA to Arf1. Left panel, representative western blot analysis of cells transfected with the 997 
indicated siRNA. The expression of Arf1 was detected with a specific antibody. Vimentin 998 
(Vim) was used as a loading control. Right panel, at 72 hpt scramble siRNA and siArf1cells 999 
were infected with RRV (MOI=5). At 12 hpi, cells were collected and the viral titer was 1000 
determined. Data represent the percentages of virus progeny, where the cells transfected 1001 
with an irrelevant siRNA (Irre), correspond to 100% infectivity. The arithmetic means ± 1002 
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